A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

British Journal of Dermatology ◽

10.1111/bjd.14493 ◽

2016 ◽

Vol 175 (2) ◽

pp. 273-286 ◽

Author(s):

K.A. Papp ◽

K. Reich ◽

C. Paul ◽

A. Blauvelt ◽

W. Baran ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Prospective Phase

Download Full-text

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.15733 ◽

2020 ◽

Author(s):

Seong Jun Seo ◽

Bong Seok Shin ◽

Joo‐Heung Lee ◽

Haeyoun Jeong

Keyword(s):

Plaque Psoriasis ◽

Korean Population ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )

British Journal of Dermatology ◽

10.1111/bjd.19147 ◽

2020 ◽

Vol 183 (2) ◽

pp. 231-241 ◽

Author(s):

A.S. Paller ◽

M.M.B. Seyger ◽

G. Alejandro Magariños ◽

J. Bagel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Paediatric Patients

Download Full-text

A phase IV randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efalizumab in patients with moderate to severe plaque psoriasis involving the scalp

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2008.11.787 ◽

2009 ◽

Vol 60 (3) ◽

pp. AB181

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Download Full-text

A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

British Journal of Dermatology ◽

10.1111/j.1365-2133.2012.11015.x ◽

2012 ◽

Vol 167 (3) ◽

pp. 649-657 ◽

Author(s):

A.B. Gottlieb ◽

R.G. Langley ◽

B.E. Strober ◽

K.A. Papp ◽

P. Klekotka ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.07.034 ◽

2012 ◽

Vol 67 (1) ◽

pp. 86-92 ◽

Author(s):

Jerry Bagel ◽

Charles Lynde ◽

Stephen Tyring ◽

Gregory Kricorian ◽

Yifei Shi ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2011.04394.x ◽

2011 ◽

Vol 27 (1) ◽

pp. 125-128 ◽

Author(s):

S. Tyring ◽

J. Bagel ◽

C. Lynde ◽

P. Klekotka ◽

E.H.Z. Thompson ◽

...

Keyword(s):

Plaque Psoriasis ◽

Patient Reported Outcomes ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Patient Reported

Download Full-text

Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.02.939 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB233 ◽

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study

European Journal of Dermatology ◽

10.1684/ejd.2010.1185 ◽

2011 ◽

Vol 21 (1) ◽

pp. 89-94 ◽

Author(s):

Rod KUNYNETZ ◽

Wayne CAREY ◽

Richard THOMAS ◽

Darryl TOTH ◽

Ted TRAFFORD ◽

...

Keyword(s):

Quality Of Life ◽

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1090830.544164 ◽

2007 ◽

Author(s):

Nico van Zandwijk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Iii ◽

Controlled Study ◽

Small Cell Lung ◽

Extensive Disease ◽

Double Blind ◽

Double Blind Placebo ◽

Response To Chemotherapy

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text